December 12, 2010, Updated September 27, 2012

TransPharma Medical, an Israeli specialty pharmaceutical company, recently announced successful results of a four-week Phase 1 clinical trial of its new self-applied ViaDerm System ViaDerm-hPTH(1-34) for the treatment of osteoporosis.

Sponsored by Eli Lilly and Company in collaboration with TransPharma Medical, a subject and investigator, blind placebo-controlled, dose escalation study of 60 healthy postmenopausal Japanese women was conducted.

“We are very pleased with the results of this study, in which we successfully demonstrated the performance of our new self-applied ViaDerm system as a product intended for home use,” says Dr. Daphna Heffetz, CEO of TransPharma Medical.

“This is an important step toward introducing the ViaDerm system as a household solution for the self-delivery of a variety of medical substances, first and foremost being hPTH(1-34) for the treatment of osteoporosis.”

The debilitating disease affects an estimated 75 million people in Europe, the US and Japan, reducing the density and quality of bone and greatly increasing the risk of fracture.

TransPharma’s ViaDerm drug delivery system incorporates a handheld electronic device, which creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch.

TransPharma currently has three drug products in clinical trials.

Fighting for Israel's truth

We cover what makes life in Israel so special — it's people. A non-profit organization, ISRAEL21c's team of journalists are committed to telling stories that humanize Israelis and show their positive impact on our world. You can bring these stories to life by making a donation of $6/month. 

Jason Harris

Jason Harris

Executive Director

Read more: